Hirabayashi Aki, Yahara Koji, Kajihara Toshiki, Sugai Motoyuki, Shibayama Keigo
Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Department of Bacteriology II, National Institute of Infectious Diseases, Tokyo, Japan.
PLoS One. 2020 Dec 17;15(12):e0243630. doi: 10.1371/journal.pone.0243630. eCollection 2020.
Enterobacterales resistant to carbapenems, a class of last-resort antimicrobials, are ranked as an "urgent" and "critical" public health hazard by CDC and WHO. IMP-type carbapenemase-containing Enterobacterales are endemic in Japan, and blaIMP-6 is one of the notable carbapenemase genes responsible for the resistance. The gene is plasmid-encoded and confers resistance to meropenem, but not to imipenem. Therefore, IMP-6-producing Enterobacterales isolates are occasionally overlooked in clinical laboratories and are referred to as 'stealth-type'. Since previous reports in Japan were confined only to some geographical regions, their distribution across prefectures and the factors affecting the distribution remain unclear. Here, we revealed the dynamics of the geographical distribution of Enterobacterales with IMP-6 phenotype associated with antimicrobial use in Japan. We utilized comprehensive national surveillance data of all routine bacteriological test results from more than 1,400 hospitals in 2015 and 2016 to enumerate Escherichia coli and Klebsiella pneumoniae isolates with the antimicrobial susceptibility pattern (phenotype) characteristic of IMP-6 (imipenem susceptible, meropenem resistant), and to tabulate the frequency of isolates with the phenotype for each prefecture. Isolates were detected in approximately half of all prefectures, and combined analysis with the national data of antimicrobial usage revealed a statistically significant association between the frequency and usage of not carbapenems but third-generation cephalosporins (p = 0.006, logistic mixed-effect regression) and a weaker association between the frequency and usage of fluoroquinolones (p = 0.043). The usage of third-generation cephalosporins and fluoroquinolones may select the strains with the IMP-6 phenotype, and contribute to their occasional spread. We expect the findings will promote antimicrobial stewardship to reduce the spread of the notable carbapenemase gene.
对碳青霉烯类耐药的肠杆菌目细菌(碳青霉烯类是一类最后的抗菌药物)被美国疾病控制与预防中心(CDC)和世界卫生组织(WHO)列为“紧急”和“严重”的公共卫生危害。含IMP型碳青霉烯酶的肠杆菌目细菌在日本呈地方性流行,blaIMP-6是导致耐药的显著碳青霉烯酶基因之一。该基因由质粒编码,赋予对美罗培南的耐药性,但对亚胺培南无耐药性。因此,产IMP-6的肠杆菌目细菌分离株在临床实验室中偶尔会被忽视,被称为“隐匿型”。由于日本此前的报告仅局限于某些地理区域,其在各辖区的分布情况以及影响分布的因素仍不清楚。在此,我们揭示了日本具有IMP-6表型的肠杆菌目细菌地理分布动态及其与抗菌药物使用的关系。我们利用2015年和2016年来自1400多家医院的所有常规细菌学检测结果的全面全国监测数据,对具有IMP-6特征性抗菌药物敏感性模式(表型)(亚胺培南敏感、美罗培南耐药)的大肠杆菌和肺炎克雷伯菌分离株进行计数,并列出各辖区具有该表型的分离株频率。在大约一半的辖区中检测到了分离株,与全国抗菌药物使用数据的综合分析显示,频率与第三代头孢菌素(而非碳青霉烯类)的使用之间存在统计学显著关联(p = 0.006,逻辑混合效应回归),与氟喹诺酮类药物使用的关联较弱(p = 0.043)。第三代头孢菌素和氟喹诺酮类药物的使用可能会选择具有IMP-6表型的菌株,并促使其偶尔传播。我们期望这些发现将促进抗菌药物管理,以减少这种显著碳青霉烯酶基因的传播。